StocksFundsScreenerSectorsWatchlists
NEPH

NEPH - Nephros Inc Stock Price, Fair Value and News

2.19USD-0.08 (-3.52%)Market Closed

Market Summary

NEPH
USD2.19-0.08
Market Closed
-3.52%

NEPH Alerts

  • 1 major insider buys recently.

NEPH Stock Price

View Fullscreen

NEPH RSI Chart

NEPH Valuation

Market Cap

23.1M

Price/Earnings (Trailing)

-13.05

Price/Sales (Trailing)

2.29

EV/EBITDA

-4.31

Price/Free Cashflow

31.85

NEPH Price/Sales (Trailing)

NEPH Profitability

EBT Margin

-45.23%

Return on Equity

-21.17%

Return on Assets

-14.91%

Free Cashflow Yield

3.14%

NEPH Fundamentals

NEPH Revenue

Revenue (TTM)

10.0M

NEPH Earnings

Earnings (TTM)

-1.8M

Earnings Growth (Yr)

94.23%

Earnings Growth (Qtr)

57.97%

Breaking Down NEPH Revenue

Last 7 days

0.9%

Last 30 days

-41.1%

Last 90 days

-36.7%

Trailing 12 Months

112.6%

How does NEPH drawdown profile look like?

NEPH Financial Health

Current Ratio

3.98

NEPH Investor Care

Shares Dilution (1Y)

1.63%

Diluted EPS (TTM)

-0.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20229.7M10.3M10.2M10.0M
20218.8M9.5M9.9M10.3M
20200008.6M
20180000
20172.5M2.8M3.3M0
20162.0M1.9M2.1M2.3M
20151.8M1.9M1.8M1.9M
20141.7M1.6M1.6M1.7M
20131.8M2.1M1.9M1.7M
20122.1M1.7M1.9M1.8M
20112.6M2.5M2.2M2.2M
201002.8M2.8M2.9M
20090002.7M

Tracking the Latest Insider Buys and Sells of Nephros Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 13, 2024
wexford capital lp
sold
-
-
-91,463
-
Mar 13, 2024
amron arthur h
acquired
-
-
91,463
-
Mar 12, 2024
amron arthur h
bought
17,129
2.4471
7,000
-
Dec 13, 2023
amron arthur h
acquired
-
-
9,291
-
Dec 13, 2023
spandow oliver j.
acquired
-
-
14,294
-
Dec 13, 2023
lask alisa
acquired
-
-
9,291
-
Dec 13, 2023
harris joseph michael
acquired
-
-
9,291
-
Dec 07, 2023
banks robert r. jr.
bought
39,646
2.2026
18,000
president and ceo
Aug 15, 2023
banks robert r. jr.
bought
3,206
1.6869
1,901
president and ceo
Aug 14, 2023
banks robert r. jr.
bought
148
1.5
99.00
president and ceo

1–10 of 50

Which funds bought or sold NEPH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
added
0.35
340,079
592,733
-%
Feb 15, 2024
WEXFORD CAPITAL LP
reduced
-0.13
7,284,820
12,742,200
2.73%
Feb 14, 2024
STATE STREET CORP
unchanged
-
30,689
54,158
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
new
-
28.00
28.00
-%
Feb 14, 2024
Granite Investment Partners, LLC
new
-
38,821
38,821
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
new
-
40,655
40,655
-%
Feb 13, 2024
Mesirow Financial Investment Management, Inc.
new
-
53,225
53,225
-%
Feb 13, 2024
ELKHORN PARTNERS LIMITED PARTNERSHIP
reduced
-29.64
43,000
110,000
0.08%
Feb 13, 2024
MORGAN STANLEY
added
120
94,226
116,858
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
added
1,003
8,295
8,629
-%

1–10 of 20

Are Funds Buying or Selling NEPH?

Are funds buying NEPH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NEPH
No. of Funds

Unveiling Nephros Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 03, 2023
cowen prime advisors llc
-
0
SC 13G
Feb 03, 2023
cowen prime advisors llc
-
0
SC 13G
Feb 03, 2023
cowen prime advisors llc
4.00%
1,431,404
SC 13G
Jan 06, 2023
intelligent fanatics capital management llc
0%
0
SC 13G/A
Feb 28, 2022
intelligent fanatics capital management llc
5.12%
525,408
SC 13G
Feb 09, 2022
cowen prime advisors llc
6%
633,050
SC 13G
Feb 08, 2022
samjo capital llc
4.2%
425,000
SC 13G/A
Jun 11, 2021
evans daron
4.7%
478,874
SC 13D/A
Jan 27, 2021
cowen prime services llc
6%
575,077
SC 13G
Oct 26, 2020
wexford capital lp
36.78%
6,664
SC 13D/A

Recent SEC filings of Nephros Inc

View All Filings
Date Filed Form Type Document
Mar 15, 2024
10-K
Annual Report
Mar 14, 2024
4
Insider Trading
Mar 14, 2024
4
Insider Trading
Mar 07, 2024
8-K
Current Report

Peers (Alternatives to Nephros Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
197.2B
40.1B
-4.86% 15.92%
34.46
4.92
-8.12% -17.45%
71.5B
19.5B
0.51% 2.89%
56.92
3.67
4.02% -22.04%
24.6B
3.9B
3.48% 6.92%
55.34
6.38
3.42% 23.09%
21.7B
14.8B
0.45% 8.95%
8.17
1.47
2.12% 209.17%
MID-CAP
10.1B
2.7B
2.33% -24.94%
-15.85
3.78
-4.68% 82.43%
9.7B
12.3B
-5.43% -4.61%
23.33
0.79
-2.44% -22.68%
9.5B
3.5B
1.79% 27.37%
33.39
2.72
4.97% 18.89%
6.9B
4.0B
-2.12% -10.90%
-51.17
1.74
1.10% 85.84%
3.5B
366.4M
0.85% 23.07%
-577.81
9.6
33.86% 89.80%
2.5B
6.6B
-3.99% 4.10%
12.8
0.38
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
53.67% -16.78%
-2.26
0.48
7.73% -1066.14%
377.2M
166.7M
-1.89% -9.35%
-4.56
2.26
6.67% -456.34%
233.9M
329.5M
1.38% -51.29%
-16.57
0.71
0.49% 64.22%
47.1M
52.3M
-32.34% -53.42%
-2.52
0.9
17.61% 19.28%
4.4M
3.7M
-1.18% 342.11%
-0.36
1.17
5.77% 8.23%

Nephros Inc News

Latest updates
Seeking Alpha • 08 Mar 2024 • 12:51 am
InvestorPlace • 07 Mar 2024 • 08:00 am
Simply Wall St • 29 Feb 2024 • 08:00 am
Seeking Alpha • 2 years ago

Nephros Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12018Q42018Q32018Q22018Q12017Q42017Q32017Q22017Q12016Q4
Revenue4.9%2,526,5002,409,0002,884,0002,187,0002,675,0002,578,0002,266,0002,736,0002,334,0002,121,0001,577,0002,529,0001,265,0001,0001,000306,000611,000916,000859,000734,000745,500
Gross Profit98.8%1,515,000762,0001,395,0001,053,0001,441,0001,360,0001,275,0001,587,0001,302,0001,225,000895,0001,491,000954,000952,000830,000467,000-----
Operating Expenses8.1%2,208,0002,043,0002,209,0002,600,0001,959,0002,162,0002,392,0002,605,0002,021,0002,157,0002,493,0002,517,0001,683,0001,463,0001,483,0001,590,000-----
  S&GA Expenses2.6%1,787,5001,743,0001,885,0002,177,0001,723,0001,718,0001,854,0001,999,0001,362,0001,544,0001,610,0001,950,0001,097,0001,069,0001,091,0001,260,000-----
  R&D Expenses42.3%358,500252,000273,000372,000194,000395,000487,000556,000609,000751,000836,000563,000-352,000-------
EBITDA Margin-1.1%-0.43-0.42-0.42-0.44-0.42-0.43-0.45-0.48-------------
Interest Expenses-25.0%3,0004,0006,0007,0007,00010,00011,00013,00015,00022,00030,00043,00026,00032,00028,000------
Income Taxes-----37,0007,00014,00021,0001,000-10,00011,000-100,0004,000-3,000-1,795,0002,0002,0002,0009,000
EBT Margin-1.5%-0.45-0.45-0.44-0.47-0.44-0.46-0.48-0.52-------------
Net Income73.1%-848,000-3,154,000-1,137,000-1,967,000-922,500-1,222,000-1,126,000-537,000-759,000-1,012,000-1,657,000-1,098,000-725,000-566,000-682,000-1,429,0001,289,000----
Net Income Margin-0.4%-0.71-0.71-0.51-0.54-0.37-0.37-0.36-0.45-------------
Free Cashflow-14.7%-195,000-170,000-1,175,000-1,831,000-335,000-923,000-117,000-78,000-------------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets8.6%11,86110,91910,38610,92710,99911,33514,95315,52817,65017,82017,99117,93618,51015,24216,64918,29411,62911,55412,01410,13810,558
  Current Assets-1.2%8,4058,5067,9148,3248,2619,11811,12211,65713,63413,62114,84014,66715,15411,75513,07014,8098,2998,1178,4377,1728,173
    Cash Equivalents-6.8%4,3074,6224,0603,8363,6343,9404,1795,4216,9737,3508,2788,1638,2495,1557,0468,9624,1663,8554,3183,6084,581
  Inventory8.9%2,4702,2682,1262,3483,1533,4884,6644,6794,4624,6495,0874,6795,3045,3854,7693,6492,5622,1282,3142,0401,864
  Net PPE72.7%15288.0098.0010711612845038472.0038230331129530229676.0081.0085.0089.0097.0091.00
  Goodwill5.4%800759800759759800759800759759759759759759759759759759759759748
Liabilities52.5%3,5032,2971,7312,0332,1181,7542,4722,1262,9012,4903,0002,3992,9373,8024,3734,6583,9404,8325,2084,5343,760
  Current Liabilities15.6%2,1131,8281,1971,4151,4121,5512,1111,7482,3901,8232,1701,4081,3252,3792,7653,1082,4283,1163,2923,1102,654
Shareholder's Equity-3.1%8,3588,6228,6558,8945,5929,58112,48113,40214,74915,33014,99115,53715,57311,44012,27613,6367,6896,7226,8065,6046,798
  Retained Earnings-0.5%-144,400-143,752-143,570-143,137-142,831-142,000-138,800-137,700-135,725-134,700-133,500-132,395-131,858-131,100-130,087-128,430-127,332-127,188-126,444-125,502-124,153
  Additional Paid-In Capital0.3%152,754152,364152,215152,021148,413148,275148,040147,781147,346146,883145,378144,801144,296139,410139,243138,953131,934130,830130,169127,974127,873
Shares Outstanding0.6%10,54410,48510,48510,48510,29710,27810,26510,21410,25810,0459,9439,883---------
Minority Interest-----3,2893,2793,2603,2423,0543,0543,0543,0533,0513,0523,0463,0403,0143,0093,0033,0003,000
Float-------9,879---60,900---43,900---17,800--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-147.0%-264562226276-195-170-1,072-1,797-335-910-117-55.00-1,526-1,817-1,720-1,840364-614-1,329-697-528
  Share Based Compensation161.7%390149194319179254277272434268281276206172179222670354150158397
Cashflow From Investing--------103-34.00--62.00--23.00--13.00----14.00--137-
Cashflow From Financing-Infinity%-3.00--2.00-74.00-111-69.00-67.00281-37.0046.00231-3.004,615-65.0028.006,638-55.001712,038-137778

NEPH Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Net revenue:  
Total net revenues$ 14,238$ 9,975
Cost of goods sold5,8335,244
Gross Margin8,4054,731
Operating expenses:  
Research and development8731,255
Depreciation and amortization214218
Selling, general and administrative8,9117,593
Total operating expenses9,9989,066
Operating loss from continuing operations(1,593)(4,335)
Other (expense) income:  
Interest expense(2)(20)
Interest income6414
Other (expense) income, net(44)64
Total other income:1858
Loss from continuing operations(1,575)(4,277)
Net loss from discontinued operations(2,829)
Net loss(1,575)(7,106)
Less: undeclared deemed dividend attributable to noncontrolling interest(276)
Net loss attributable to Nephros, Inc. shareholders$ (1,575)$ (7,382)
Net loss per common share, basic from continuing operations$ (0.15)$ (0.42)
Net loss per common share, diluted from continuing operations(0.15)(0.42)
Net loss per common share, basic from discontinued operations(0.28)
Net loss per common share, diluted from discontinued operations(0.28)
Net loss per common share, basic(0.15)(0.70)
Net loss per common share, diluted(0.15)(0.70)
Net loss per common share, basic, attributable to continuing noncontrolling interest(0.03)
Net loss per common share, diluted, attributable to continuing noncontrolling interest(0.03)
Net loss per common share, basic, attributable to Nephros, Inc, shareholders(0.15)(0.73)
Net loss per common share, diluted, attributable to Nephros, Inc, shareholders$ (0.15)$ (0.73)
Weighted average common shares outstanding, basic10,386,01810,297,134
Weighted average common shares outstanding, diluted10,386,01810,297,134
Comprehensive loss:  
Other comprehensive loss, foreign currency translation adjustments, net of tax$ (14)
Comprehensive loss(1,575)(7,120)
Comprehensive loss attributable to continuing noncontrolling interest(276)
Comprehensive loss attributable to Nephros, Inc. shareholders(1,575)(7,396)
Product [Member]  
Net revenue:  
Total net revenues14,1109,929
Royalty And Other Revenues [Member]  
Net revenue:  
Total net revenues$ 128$ 46

NEPH Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 4,307$ 3,634
Accounts receivable, net1,4961,286
Inventory2,4703,153
Prepaid expenses and other current assets132188
Total current assets8,4058,261
Property and equipment, net152116
Lease right-of-use assets1,807984
Intangible assets, net381423
Goodwill759759
License and supply agreement, net271402
Other assets8654
TOTAL ASSETS11,86110,999
Current liabilities:  
Current portion of secured note payable71
Accounts payable873740
Accrued expenses794285
Current portion of lease liabilities446316
Total current liabilities2,1131,412
Equipment financing, net of current portion1
Lease liabilities, net of current portion1,390705
TOTAL LIABILITIES3,5032,118
COMMITMENTS AND CONTINGENCIES (Note 17)
STOCKHOLDERS’ EQUITY:  
Preferred stock, $.001 par value; 5,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022
Common stock, $.001 par value; 40,000,000 shares authorized at December 31, 2023 and 2022; 10,543,675 and 10,297,429 shares issued and outstanding at December 31, 2023 and 2022, respectively1010
Additional paid-in capital152,754148,413
Accumulated deficit(144,406)(142,831)
Subtotal8,3585,592
Noncontrolling interest3,289
TOTAL STOCKHOLDERS’ EQUITY8,3588,881
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 11,861$ 10,999
NEPH
Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells medical device products for patients with renal disease, including a second generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it manufactures and sells water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and Nanoguard brands for the food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
 CEO
 WEBSITEwww.nephros.com
 EMPLOYEES27

Nephros Inc Frequently Asked Questions


What is the ticker symbol for Nephros Inc? What does NEPH stand for in stocks?

NEPH is the stock ticker symbol of Nephros Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nephros Inc (NEPH)?

As of Thu Mar 28 2024, market cap of Nephros Inc is 23.09 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NEPH stock?

You can check NEPH's fair value in chart for subscribers.

What is the fair value of NEPH stock?

You can check NEPH's fair value in chart for subscribers. The fair value of Nephros Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nephros Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NEPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nephros Inc a good stock to buy?

The fair value guage provides a quick view whether NEPH is over valued or under valued. Whether Nephros Inc is cheap or expensive depends on the assumptions which impact Nephros Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NEPH.

What is Nephros Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Mar 28 2024, NEPH's PE ratio (Price to Earnings) is -13.05 and Price to Sales (PS) ratio is 2.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NEPH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Nephros Inc's stock?

In the past 10 years, Nephros Inc has provided 0.213 (multiply by 100 for percentage) rate of return.